Elutia Inc., a commercial-stage company, engages in developing and commercializing drug-eluting biomatrix technology to enhance surgical outcomes. The company is headquartered in Silver Spring, Maryland.
| Revenue (TTM) | $12.14M |
| Gross Profit (TTM) | $7.01M |
| EBITDA | $-21.37M |
| Operating Margin | -243.10% |
| Return on Equity | 0.00% |
| Return on Assets | -34.70% |
| Revenue/Share (TTM) | $0.28 |
| Book Value | $0.36 |
| Price-to-Book | 2.56 |
| Price-to-Sales (TTM) | 3.56 |
| EV/Revenue | 3.81 |
| EV/EBITDA | -3.33 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 5.50% |
| Shares Outstanding | $44.29M |
| Float | $29.45M |
| % Insiders | 3.51% |
| % Institutions | 43.91% |
Volatility is currently expanding
ROSWELL, Ga., Aug. 18, 2026 (GLOBE NEWSWIRE) -- Cellution Biologics Inc. (“Cellution Biologics” or the “Company”), a biologics company focused on developing, manufacturing and commercializing advanced human tissue-based products, today announced the completion of its acquisition of the SimpliDerm hydrated human acellular dermal matrix (ADM) business from Elutia Inc. (Nasdaq: ELUT).
Deal valued at $11 million in cash, with $8 million at closing and up to $3 million in additional milestone payments over the next 18 months Divestiture further concentrates Elutia's attention and resources on the development and commercialization of NXT-41x NXT-41x is an antibiotic-eluting biomatrix designed to address post-operative infection in the $1.5 billion U.S. plastic and reconstructive surgery market NXT-41x clearance expected in the first half of 2027 GAITHERSBURG, Md., Aug. 18, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix technologies, today announced it completed the sale of its SimpliDerm® human acellular dermal matrix business to Cellution Biologics Inc. for total consideration of up to $11 million.
Elutia Inc. (ELUT) Q2 2026 Earnings Call Transcript
Funded through launch: secured up to $26 million of capital without an equity offering The unmet need is real: 86% of surgeons surveyed say the matrices they use today increase infection risk The demand is strong: 96% of surgeons surveyed are interested in adopting NXT-41x; 92% responded they would champion it at their hospital value analysis committee On track: NXT-41 FDA clearance decision expected in 4Q 2026; NXT-41x FDA clearance decision expected in 1H 2027 GAITHERSBURG, Md., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix technologies, today provided a business update and announced financial results for the second quarter ended June 30, 2026.
$10 million funded at closing; second $5 million tranche unlocked upon FDA 510(k) clearance of NXT-41x Preserves shareholder value by funding commercialization of Elutia's next-generation antibiotic-eluting biomatrix without an equity offering NXT-41x targets the 15–20% post-operative infection rates in multiple complex plastic and reconstructive surgical procedures GAITHERSBURG, Md., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix technologies, today announced a $15 million growth capital financing agreement with Avenue Capital Group (“Avenue Capital”).
GAITHERSBURG, Md., July 31, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix technologies, today announced that it will release its second quarter 2026 financial results after market close on Thursday, August 13, 2026.
Elutia Signs Definitive Agreement to Sell SimpliDerm® in Transaction Valued at up to $11 Million, Strengthening Balance Sheet Ahead of NXT-41x Launch
GAITHERSBURG, Md., June 11, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) ("Elutia" or the "Company"), a pioneer in drug-eluting biomatrix technologies, today announced that Dr. Randy Mills, Chief Executive Officer, and Dr. Michelle Williams, Chief Scientific Officer, will present and host one-on-one meetings with investors at the Planet MicroCap Showcase 2026 at the Bellagio in Las Vegas, Nevada on June 17–18, 2026.
GAITHERSBURG, Md., May 18, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) ("Elutia" or the "Company"), a pioneer in drug-eluting biomatrix technologies, today announced that it granted equity awards on May 13, 2026 to one new employee as an inducement award under the Elutia Inc. 2026 Inducement Award Plan (the “Plan”).
NXT-41 review advancing collaboratively with FDA, informing NXT-41x submission preparations Brought a new automated manufacturing process online, supporting a gross margin target of more than 80% at scale Chief Commercial Officer Pete Ligotti's initial surgeon engagement confirming significant unmet need and market opportunity Strong balance sheet with $36.5 million in cash and escrowed proceeds from the BioEnvelope business divestiture Conference call today at 5:00 p.m. ET / 2:00 p.m.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on ELUT and any ticker you trade — then tracks every position and per-strategy win rate.
